News | November 20, 2012

Lantheus Extends NTP Radioisotopes Contract to Ensure Supply of LEU-Produced Molybdenum-99

Agreement demonstrates company’s long-term commitment to eliminate use of HEU-produced products

November 20, 2012 — Lantheus Medical Imaging Inc. and two medical isotope producers have agreed to work together to help ensure supplies of potentially life-saving nuclear medicine using molybdenum-99 (Mo-99) sourced from low enriched uranium (LEU).

Lantheus announced that the company has extended its contract with NTP Radioisotopes (Pty) Ltd., a subsidiary of the South African Nuclear Energy Corp. Ltd (Necsa), to receive a significant and increasing supply of Mo-99 produced from LEU targets through Dec. 31, 2017. Under the terms of the five-year agreement, NTP and the Australian Nuclear Science and Technology Organization (ANSTO) will become the largest suppliers of LEU Mo-99 to Lantheus in the future. Lantheus actively supports the U.S. government initiative to encourage the use of LEU in the manufacture of medical isotopes.

The extended agreement also provides for a separate supply of Mo-99 from the Institute for Radioelements (IRE), giving Lantheus access to a reliable and globally diversified supply of Mo-99 for the duration of the extended term. The ongoing supply relationships with NTP, ANSTO and IRE provide Lantheus with access to Mo-99 from three processing facilities and six research reactors in Africa, Australia and Europe. Additionally, Lantheus continues to receive Mo-99 from its Canadian supplier; this agreement has also recently been extended.

“This agreement, combined with our recent agreement with our Canadian supplier, achieves our goal of securing a globally diversified and balanced Mo-99 supply chain to meet the needs of the nuclear medicine community now and well into the future,” said Don Kiepert, Lantheus president and CEO. “Additionally, we are committed to promoting global nuclear safety by continuing to increase our use of LEU-sourced Mo-99. This agreement with NTP further demonstrates that commitment. In 2010, we were the first company in North America to gain U.S. Food and Drug Administration (FDA) approval for the commercial sale and distribution of a technetium generator using Mo-99 produced from LEU targets.”

“A global milestone was achieved in June 2009 when the SAFARI-1 reactor started up its core without any highly-enriched uranium (HEU) fuel,” said Phumzile Tshelane, CEO of Necsa and chairperson of the NTP Radioisotopes Board of Directors. This accomplishment marked the beginning of the first-ever LEU-based production process of Mo-99, which resulted in the successful delivery of the first commercial scale shipment of this product into the United States in July 2010.

Tshelane drew attention to the announcement made by Necsa/NTP during the “Next Generation Nuclear Security Summit” held in Washington in 2010, where Necsa/NTP committed to supply LEU-based medical isotopes to the United States. “We are proud that a purely South African technological advancement has contributed so significantly to nuclear non-proliferation efforts, while simultaneously enhancing the lives of millions using nuclear medicine. This firmly illustrates both South Africa and Necsa/NTP’s commitment to the utilization of nuclear technology for peaceful purposes,” said Tshelane.

“The importance of our collaborative efforts to provide medical isotopes derived from LEU has been described by the U.S. National Nuclear Security Administration as a critical step toward moving away from the use of HEU in medical isotope production around the world,” said Adi Paterson, ANSTO CEO. “These efforts led ANSTO, NTP and Lantheus to be named runners up in a poll of '2011 Arms Control Persons of the Year' for our groundbreaking work to produce medical isotopes using LEU instead of HEU. We believe that demand for LEU moly will increase on a global basis as more customers embrace nuclear non-proliferation goals.”

"We support this agreement between Lantheus and our colleagues and are willing to actively contribute to the global security of supply of medical radioisotopes, particularly in the United States,” said Jean-Michel Vanderhofstadt, director general of IRE. “Also paramount is our full commitment for the fastest possible conversion of our process and facility to a unique solution for the secure manufacturing of medical radioisotopes based on non-HEU derived processes. Our technical cooperation with NTP and ANSTO is a valuable asset in that respect. This conversion program is currently running full steam ahead in our Belgian plant, with the most appreciated support of the DoE and our authorities in Europe."

For more information: www.lantheus.com, www.ntp.co.za

Related Content

ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging | August 18, 2017
August 18, 2017 — The American Society of Nuclear Cardiology (ASNC) has released a joint expert consensus document wi
Houston Methodist Hospital Enters Multi-Year Technology and Research Agreement With Siemens Healthineers
News | Imaging | August 17, 2017
Houston Methodist Hospital and Siemens Healthineers have entered into a multi-year agreement to bring cutting-edge...
Study Demonstrates First Human Application of Novel PET Tracer for Prostate Cancer

Transaxial 11Csarcosine hybrid PET/CT showed a (triangulated) adenocarcinoma in the transition zone of the anterior right prostate gland on PET (A), CT (B), and a separately obtained T2?weighted MR sequence (C) with resulting PET/MRI registration (D). Image courtesy of M. Piert et al., University of Michigan, Ann Arbor, Mich.

News | Radiopharmaceuticals and Tracers | August 16, 2017
In the featured translational article in the August issue of The Journal of Nuclear Medicine, researchers at the...
PET/CT Tracer Identifies Vulnerable Lesions in Non-Small Cell Lung Cancer Patients

Example of a patient with an upper left lung NSCLC: A: FDG; B: FDG PET/CT; C: Planning radiotherapy based on FDG (66Gy) with BTVm (GTV), CTV and PTV; D: PET FMISO E: FMISO PET/CT; F: boost based on the FMISO PET (76Gy) with BTVh (biological hypoxic target volume) and PTV boost. Credit: QuantIF – LITIS EA 4108 – FR CNRS 3638, Henri Becquerel Cancer Center, Rouen, France

News | PET-CT | July 14, 2017
July 14, 2017 — Fluorine-18 (18F)-fluoromisonidazole (FMISO) is a positron emission tomography (PET)...
Novel PET Tracer Detects Small Blood Clots

PET images (MIP 0-60 min) of three Cynomolgus monkeys. Strong signals are detected at the sites where inserted catheters had roughened surfaces. Almost no other background signal is visible. Only accumulation in the gallbladder becomes visible at the bottom of the image. Credit: Piramal Imaging GmbH, Berlin Germany.

News | PET Imaging | July 07, 2017
July 7, 2017 — Blood clots in veins a
Sponsored Content | Videos | Clinical Decision Support | June 29, 2017
Rami Doukky, M.D., system chair, Division of Cardiology, professor of medicine, Cook County Health and Hospitals Syst
Dual-Agent PET/MR With Time of Flight Detects More Cancer

Tc-99m MDP bone scan (left) is negative for osseous lesions. NaF/FDG PET/MRI (right and second slide) confirms absence of bone metastases, but shows liver metastases. Image courtesy of Stanford University.

News | PET-MRI | June 20, 2017
Simultaneous injections of the radiopharmaceuticals fluorine-18 fluorodeoxyglucose (18F-FDG) and 18F-sodium fluoride (...
Combined Optical and Molecular Imaging Could Guide Breast-Conserving Surgery

WLE specimen from a patient with a grade 3, ER-/HER2-, no special type (NST) carcinoma. (A) Cerenkov image; (B) Grey-scale photographic image overlaid with Cerenkov signal. An increased signal from the tumor is visible (white arrows); mean radiance is 871 ± 131 photons/s/cm2/sr, mean TBR is 3.22. Both surgeons measured the posterior margin (outlined in blue) as 2 mm (small arrow); a cavity shaving would have been performed if the image had been available intraoperatively. The medial margin (outlined in green) measured >5 mm by both surgeons. Pathology ink prevented assessing the lateral margin; a phosphorescent signal is visible (open arrows). (C) Specimen radiography image. The absence of one surgical clip to mark the anterior margin, and the odd position of the superior margin clip (white arrow) prevented reliable margin assessment. (D) Combined histopathology image from two adjacent pathology slides on which the posterior margin (bottom of image) and part of the primary tumor are visible (open arrows). The distance from the posterior margin measured 3 mm microscopically (double arrow). The medial margin is > 5 mm (not present in image). Credit: A. D. Purushotham, M.D., King’s College London, UK

News | Nuclear Imaging | June 20, 2017
June 20, 2017 — Breast-conserving surgery (BCS) is the primary treatment for early-stage...
Overlay Init